The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

MOGAD (MOG Antibody-Associated Disease)

Autoimmune Demyelinating CNS Disorder

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Nöroloji department. Book Appointment →

What is MOGAD (MOG Antibody-Associated Disease)?

Distinct CNS demyelinating disorder defined by serum antibodies against MOG (cell-based assay positive).

Recognized as separate entity from MS and NMOSD since ~2017-2020.

Phenotypes: optic neuritis (most common, often bilateral), transverse myelitis, ADEM (especially children), brainstem/cortical encephalitis.

Can be monophasic (especially after initial ADEM) or relapsing.

Symptoms

Optic neuritis: rapid vision loss (often severe), eye pain with movement, swelling of optic disc; bilateral in 50%.
Transverse myelitis: weakness, sensory level, bowel/bladder dysfunction, pain.
ADEM (children): encephalopathy, multifocal neurological deficits, fever, headache.
Brainstem syndromes: ataxia, diplopia, intractable hiccup/vomiting (can mimic NMOSD).
Cortical encephalitis with seizures (FLAMES syndrome).
MRI: longitudinally extensive myelitis (LETM), perineural optic enhancement, cortical lesions.

Risk Factors

Age: bimodal — children (often ADEM) and adults.
No clear gender predominance.
Post-infectious or post-vaccination triggers in some cases.
Distinct genetic/HLA profile vs MS or NMOSD-AQP4.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Acute optic neuritis, especially severe or bilateral.
  • Transverse myelitis with longitudinally extensive lesion.
  • Acute disseminated encephalomyelitis (ADEM).
  • Recurrent demyelinating events without typical MS features.
  • Atypical demyelinating syndrome with seizures (cortical FLAMES).

Treatment Methods

01
Diagnosis: serum MOG-IgG (cell-based assay) — high titer specific. CSF often normal/inflammatory; oligoclonal bands less common than MS.
02
MRI brain and spine; OCT for optic nerve assessment.
03
Acute attack: high-dose IV methylprednisolone (1 g/day × 3-5 days), followed by oral prednisone taper (often slow, 6-12 months).
04
Severe/refractory attacks: plasma exchange (PLEX) or IVIG.
05
Relapse prevention (controversial criteria): IVIG, rituximab, mycophenolate, oral steroids, tocilizumab.
06
Avoid: interferon-beta, glatiramer acetate (MS drugs ineffective), natalizumab, fingolimod (may worsen).
07
Slow steroid taper to prevent relapse (especially in ON).
08
Monitor MOG titer (declining titer suggests monophasic course).
09
Better visual recovery than NMOSD-AQP4 generally; but visual outcomes can still be poor.
10
Pediatric ADEM: usually monophasic, good prognosis; observation often sufficient.

Which Department to Visit?

You can visit our Nöroloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Nöroloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.